Last deal

Amount

Post-IPO Equity

Stage

20.03.2019

Date

3

all rounds

$275.92M

Total amount

date founded

Financing round

General

About Company
MacroGenics is a biotech company that develops immunotherapeutics for autoimmune disorders, cancer, and infectious diseases.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2000

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

The company's products include monoclonal antibodies and vaccines to prevent infections, and it is focused on developing antibody-based therapeutics for the treatment of cancer using its Fc engineering and Dual Activating ReTargeting technologies. MacroGenics has a broad pipeline of product candidates and multiple partnerships with leading pharmaceutical and biotech companies. The company values its employees and promotes a culture of innovation, open communication, and teamwork.
Contacts

Contact Email

Phone number

Social url

Similar Companies
999
Xencor

Xencor

Xencor is a clinical-stage biopharmaceutical company that provides protein engineering technology platforms in the biotechnology industry.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Monrovia, CA, USA

total rounds

11

total raised

$482.6M

count Of Investments

1
Inimmune

Inimmune

Inimmune is a biotech company developing immunotherapeutics for various diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Missoula, MT, USA

total rounds

2

total raised

$22.59M
ImmunoGen

ImmunoGen

ImmunoGen is a clinical-stage biotechnology company that develops antibody-based anticancer therapeutics.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Waltham, MA, USA

total rounds

7

total raised

$300.5M
Morphotek

Morphotek

Morphotek is a biotech company that develops protein and antibody products using gene evolution technology.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Exton, PA 19341, USA

total rounds

5

total raised

$78.5M

Financials

Funding Rounds
11
3

Number of Funding Rounds

$275.92M

Money Raised

Their latest funding was raised on 20.03.2019. Their latest investor Nextech Venture. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
12.02.2019
$110M
31.01.2011
$12.02M
BB Biotech Ventures

BB Biotech Ventures

BB BIOTECH VENTURES is a healthcare-focused venture capital fund.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Biotechnology, Venture Capital, Health Care

Location

Zürich, Switzerland

count Of Investments

41

count Of Exists

6
Co-Investors
Investors
18
4

Number of lead investors

18

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Series D
No
Series C, Series D
No
Series D
Nextech Venture

Nextech Venture

Nextech Venture is a Swiss venture capital firm focusing on precision therapies in oncology.

Sector

Open End and Miscellaneous Investment Vehicles

Subsector

Open End and Miscellaneous Investment Vehicles

Location

Zürich, Switzerland

count Of Investments

3
Red Abbey Venture Partners

Red Abbey Venture Partners

Red Abbey Venture Partners is a life sciences investment firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Baltimore, MD, USA

count Of Investments

16

count Of Exists

4
CIDC Consultants

CIDC Consultants

CIDC Consultants is a venture capital firm in Taiwan that focuses on production, trade, services, and investments in technology businesses.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Consulting, Financial Services, Venture Capital

Location

Taipei City, Taiwan

count Of Investments

4

count Of Exists

3
Acquisitions
2
Acquiree Name 
Date 
Price 
Acquisition Name 
Raven Biotechnologies acquired by MacroGenics

Raven Biotechnologies acquired by MacroGenics

acquirer

MacroGenics
MacroGenics

date

17.07.2008

type

Acquisition
Raven Biotechnologies

Raven Biotechnologies

Raven Biotechnologies develops monoclonal antibody therapeutics for cancer treatment.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

South San Francisco, CA, USA

total rounds

2

total raised

$88.3M

Eliance Biotechnology acquired by MacroGenics

acquirer

MacroGenics
MacroGenics

date

07.06.2002

type

Acquisition

Eliance Biotechnology

Eliance Biotechnology is a vaccine research and discovery company.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Location

Dallas, TX, USA

People

Founders
5

Ruedi Aebersold

Prof. Dr. Ruedi Aebersold (co-founder) is one of the pioneers in the field of proteomics. He is known for developing a series of methods that have found wide application in analytical protein chemistry and proteomics. In 2000 he co-founded the Institute for Systems Biology in Seattle, US, and in 2005 the Institute of Molecular Systems Biology at the ETH Zurich. Ruedi Aebersold also serves on the Scientific Advisory Committees of numerous academic and private sector research organizations and is a member of several editorial boards in the fields of protein science, genomics, and proteomics.

current job

Institute for Systems Biology
Institute for Systems Biology

organization founded

2

Ruedi Aebersold

Jeffrey V. Ravetch

Dr. Jeffrey Ravetch is a Co-Founder & serves as an Advisor at Nuvig Therapeutics. Dr. Ravetch is a Co-Founder of MacroGenics. He also serves as a Venture Partner at Catalio Capital Management. He received his B.S. in Molecular Biophysics and Biochemistry from Yale University in 1973, a Ph.D. from Rockefeller University - Cornell Medical School in 1978, and his M.D. from Cornell University Medical College.

current job

MacroGenics
MacroGenics

organization founded

1

Jeffrey V. Ravetch

Leroy Hood
Leroy Hood

Leroy Hood

Leroy Hood is currently President of the Institute for Systems Biology. His research has focused on the study of molecular immunology, biotechnology, and genomics. His professional career began at the California Institute of Technology where he and his colleagues pioneered four instruments—the DNA gene sequencer and synthesizer, and the protein synthesizer and sequencer—which comprise the technological foundation for contemporary molecular biology. In particular, the DNA sequencer has revolutionized genomics by allowing the rapid, automated sequencing of DNA, which played a crucial role in contributing to the successful mapping of the human genome during the 1990s. In 1992, Hood moved to the University of Washington as founder and Chairman of the cross-disciplinary Department of Molecular Biotechnology. In 2000, he co-founded the Institute for Systems Biology in Seattle, Washington to pioneer systems approaches to biology and medicine. Hood is a member of the National Academy of Sciences, the American Philosophical Society, the American Association of Arts and Sciences, and the Institute of Medicine. He has also played a role in founding numerous biotechnology companies, including Amgen, Applied Biosystems, Systemix, Darwin, and Rosetta. Hood received an M.D. from Johns Hopkins School of Medicine and a Ph.D. in Biochemistry from the California Institute of Technology. He has published more than 600 peer-reviewed papers, has 14 issued patents, and has co-authored textbooks in biochemistry, immunology, molecular biology, and genetics.

current job

Institute for Systems Biology
Institute for Systems Biology

Leroy Hood

Scott Koenig
Scott Koenig

Scott Koenig

Dr. Scott Koenig has been President and Chief Executive Officer of MacroGenics since September 2001. Prior to joining MacroGenics, he served as Senior Vice President of Research at MedImmune, Inc., where he participated in the selection and maturation of the company's product pipeline for 11 years. From 1984 to 1990, he worked in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS. Currently, he is Chairman of the Board of Directors at Applied Genetic Therapy Corporation, and serves as a Board member of MacroGenics, BIO, Children’s Research Institute of Children’s National Medical Center, the AERAS Clinical and Epidemiological Technical Advisory Board, and the Cornell University Council.

current job

MacroGenics
MacroGenics

organization founded

1

Scott Koenig

Employee Profiles
97
Eric Risser

Eric Risser

Chief Operating Officer

Julie Whittaker

Senior talent acquisition specialist

Brian Ghuzzi

Associate director, manufacturing sciences and technology

Ann Easton

Associate scientist

Raul Perez-Olle

Vice president, medical affairs

Dominick Southmayd

Director of engineering and facilities

Harish Krishnaswamy

Harish Krishnaswamy

Sr. Director Of Business Development

Patrick Grogan

Total rewards and systems manager

Activity

Recent News
12
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

week